Skip to content

What we do

We repair tissues and regenerate organs
using cell signaling technology.

Our first target is the liver space. The liver is the master organ of the body, and loss of its function causes failure of other vital organs and death.

Cellaïon aims to stop progression of chronic liver disease, control inflammation, stop fibrous tissue accumulation and eventually allow organ recovery and regeneration.

Our lead compound HepaStem® acts as a therapeutic cargo, delivering to the liver and inflamed tissues appropriate immunomodulatory signals with specific anti-inflammatory, anti-fibrotic and regenerative activities.

Our treatment covers the wide spectrum of liver diseases, from the highly life-threatening Acute-on-Chronic Liver-Failure (ACLF) and Acute Alcoholic Hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by Non-Alcoholic Steatohepatitis (NASH).

Genetic modification of HepaStem® allows to address specific targets in selected diseases.

Thanks to our allogeneic platform our of the shelf product and our multiple patients can be treated from one single tissues sourcing.

More than 100 patients have already received HepaStem®, easily administered by simple peripheral vein infusion, and the very high safety profile is now established with more that 10 years follow up.

Our proof of concept trial in ACLF is ongoing in many European countries and will be further extended in the US.

ACFL

ACUTE-ON-CHRONIC LIVER FAILURE

Acute-on-Chronic Liver Failure (ACLF), a well characterized clinical entity affecting patients with chronic liver disease including cirrhosis, and characterized by a sudden deterioration of the liver, followed by other vital organs such as kidney, brain, lung or heart. ACLF has mortality from 42% up to 75% at 3 months.

NASH

Non-alcoholic Steatohepatitis

Progressive Non-Alcoholic Steatohepatitis is the most severe manifestation of Non-alcoholic fatty liver disease (NAFLD). NASH is closely related to the triple epidemic of obesity, hyperlipidemia and diabetes type 2. The fat chronic deposits can induce liver injury and a sustained inflammation. NASH can progress to more serious disease stages, such as advanced fibrosis, cirrhosis or liver cancer.

AAH

Acute Alcoholic hepatitis

Acute Alcoholic Hepatitis is the inflammation of the liver caused by drinking excessive amounts of alcohol. The disease can be sudden with a high mortality rate.

AD

ACUTE DECOMPENSATED CIRRHOSIS

Decompensated Cirrhosis is defined as an acute deterioration in liver function in a patient with cirrhosis and is characterised by jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome or variceal haemorrhage. Patients with AD can develop ACLF.

 

Do you want to know more?

Send us an email

Lire la vidéo